CC
EUCRW

Centiva Capital’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

Centiva Capital’s Portfolio EUCRW Stock Details EUCRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-38,893
Closed -$35K – 1733
2021
Q1 		$35K Buy
+38,893
New +$63K ﹤0.01% 1094

Other funds holding EUCRW

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Centiva Capital's EUCRW Position: Q2 2021 in Review

Centiva Capital sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q2 2021, closing a stake of 38,893 shares — an estimated $35K sold.

Centiva Capital first reported a position in EUCRW in Q1 2021 and held it in 1 quarter. The position peaked at $35K in Q1 2021. 19 funds tracked by Wall St. Rank hold EUCRW as of Q2 2021.

  • Centiva Capital reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q2 2021 after selling out during the quarter.
  • Centiva Capital sold 38,893 Eucrates Biomedical Acquisition Corp. Warrant shares in Q2 2021, an estimated $35K.
  • Centiva Capital first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q1 2021 and held it in 1 quarter.
  • Centiva Capital's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $35K in Q1 2021.
  • 19 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q2 2021.

Based on Centiva Capital's 13F filing for Q2 2021, filed 16 Aug 2021.